Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus TECHNETIUM TC 99M MEDRONATE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus TECHNETIUM TC 99M MEDRONATE KIT.
MPI INDIUM DTPA IN 111 vs TECHNETIUM TC-99M MEDRONATE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Technetium Tc-99m medronate (MDP) is a bone-seeking radiopharmaceutical that binds to calcium ions in hydroxyapatite crystals of bone. Uptake is proportional to osteoblastic activity and regional blood flow, allowing scintigraphic imaging of skeletal structures.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
Intravenous injection: 370-1110 MBq (10-30 mCi) for bone imaging. Adult dose is administered once for each imaging procedure.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life: 6.02 hours (range 5.8–6.3 hours) in patients with normal renal function; prolonged in renal impairment.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Renal: approximately 50% of injected dose excreted unchanged in urine within 24 hours. Biliary/fecal: less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical